2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
2
Unknown
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
1841
Neoplasms
1230
Colorectal Neoplasms
1046
Carcinoma, Non-Small-Cell Lung
996
Stomach Neoplasms
787
Carcinoma, Hepatocellular
780
Lung Neoplasms
756
Prostatic Neoplasms
682
Pancreatic Neoplasms
567
Rectal Neoplasms
444
Colonic Neoplasms
401
Neoplasm Metastasis
400
Ovarian Neoplasms
399
Uterine Cervical Neoplasms
395
Recurrence
380
Leukemia, Myeloid, Acute
367
Esophageal Neoplasms
352
Multiple Myeloma
340
Lymphoma
330
Head and Neck Neoplasms
326
Melanoma
306
Precursor Cell Lymphoblastic Leukemia-Lymphoma
288
Brain Neoplasms
263
Urinary Bladder Neoplasms
249
Nasopharyngeal Carcinoma
221
Liver Neoplasms
221
Leukemia
217
Lymphoma, Large B-Cell, Diffuse
213
Polycystic Ovary Syndrome
206
Squamous Cell Carcinoma of Head and Neck
200
Interventions
Paclitaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Advanced Non-squamous Non-small-cell Lung Cancer
×
Clear all
NCT04416035
2020-08-31
NSCLC
Zhejiang Teruisi Pharmaceutical Inc.
Phase 3
Unknown
608 enrolled